ResMed Posts Strong Q3 2026 Growth on Margin Expansion and Digital Health Push
Event summary
- Revenue up 11% YoY to $1.4B, with 8% constant currency growth.
- GAAP gross margin expanded by 290 bps to 62.2%, driven by cost efficiencies and product mix.
- Non-GAAP net income increased by 20% YoY to $417M, with EPS up 21% to $2.86.
- $554M in operating cash flow, with $262M returned to shareholders via buybacks and dividends.
- Launched AirTouch F30i Comfort full face mask in the U.S., expanding product portfolio.
The big picture
ResMed's Q3 2026 results highlight its strong position in the sleep and breathing health market, with double-digit revenue growth and significant margin expansion. The company is leveraging cost efficiencies and digital health investments to drive profitability, while expanding its product portfolio and global footprint. These moves align with broader industry trends toward home healthcare solutions and AI-powered health technologies.
What we're watching
- Execution Risk
- Whether ResMed can sustain its gross margin expansion amid rising SG&A expenses tied to VirtuOx integration and marketing investments.
- Digital Health Scaling
- The pace at which ResMed scales its digital health capabilities, a key strategic focus for future growth.
- Global Expansion
- How the new U.S. distribution center in Indiana will impact operational efficiency and market reach.
Related topics